In the current manuscript, we demonstrated the capability of our migration-based device to isolate TICs in triple negative breast cancer (TNBC), which encompasses molecular subtypes lacking expression of estrogen receptor (ER), progesterone receptor (PR), and amplification of Her2. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.